A detailed history of Spotlight Asset Group, Inc. transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Spotlight Asset Group, Inc. holds 20,000 shares of RLMD stock, worth $7,200. This represents 0.04% of its overall portfolio holdings.

Number of Shares
20,000
Previous 20,000 -0.0%
Holding current value
$7,200
Previous $93,000 35.48%
% of portfolio
0.04%
Previous 0.07%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 18, 2022

SELL
$18.3 - $37.02 $187,849 - $380,010
-10,265 Reduced 33.92%
20,000 $740,000
Q2 2021

Aug 11, 2021

BUY
$29.55 - $39.15 $168,435 - $223,155
5,700 Added 23.2%
30,265 $969,000
Q1 2021

Apr 07, 2021

BUY
$31.52 - $39.28 $58,501 - $72,903
1,856 Added 8.17%
24,565 $865,000
Q4 2020

Feb 08, 2021

BUY
$29.88 - $39.8 $678,544 - $903,818
22,709 New
22,709 $728,000

Others Institutions Holding RLMD

About RELMADA THERAPEUTICS, INC.


  • Ticker RLMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,608,500
  • Market Cap $10.3M
  • Description
  • Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...
More about RLMD
Track This Portfolio

Track Spotlight Asset Group, Inc. Portfolio

Follow Spotlight Asset Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Spotlight Asset Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Spotlight Asset Group, Inc. with notifications on news.